SC
CRL icon

Scotia Capital’s Charles River Laboratories CRL Stock Holding History

Scotia Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,424
Closed -$588K – 880
2021
Q3 		$588K Buy
+1,424
New +$591K ﹤0.01% 603

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scotia Capital's CRL Position: Q4 2021 in Review

Scotia Capital sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 1,424 shares — an estimated $588K sold.

Scotia Capital first reported a position in CRL in Q3 2021 and held it in 1 quarter. The position peaked at $588K in Q3 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

  • Scotia Capital reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
  • Scotia Capital sold 1,424 Charles River Laboratories shares in Q4 2021, an estimated $588K.
  • Scotia Capital first reported a position in Charles River Laboratories in Q3 2021 and held it in 1 quarter.
  • Scotia Capital's Charles River Laboratories position peaked at $588K in Q3 2021.
  • 707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on Scotia Capital's 13F filing for Q4 2021, filed 11 Feb 2022.